check_circleStudy Completed

Erectile Dysfunction

Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study

Trial purpose

The study will be conducted as a multi-center, randomized, double-blinded, placebo controlled, crossover design. The investigational drug (vardenafil ODT (Orally Disintegrating Tablet)/placebo) will be given as a single administration at a dose of 10 mg vardenafil ODT during Period 1 or 2; the blinded matching placebo will be given as a single administration during the opposing period. The random code will determine the order of active drug (vardenafil ODT) and placebo for each subject. Blood pressure and heart rate profiles will be recorded by automated device pre-dose for 8 hours post-dose during Periods 1 and 2. The non investigational drug product (vasodilator), Procardia XL, will be background treatment for hypertension, taken daily by each subject. All subjects must be stable on the vasodilator for at least 4 weeks prior to Day 1 of Period 1. Special conditions for this study include the requirement that all subjects will be male, are between the ages of 65 and 80 years, and will have a diagnosis of erectile dysfunction (ED), as well as hypertension. Planned sample size will be 40 subjects evaluable for the primary analysis. Of the 40 subjects valid for this analysis, 20 will be between the ages of 65 and 69 years, and 20 subjects will be between the ages of 70 and 80 years. The total duration of the study will be approximately one year from first subject treated to last subject treated, including replacement of any subjects who fail to complete both periods of crossover dosing.

Key Participants Requirements

Sex

Male

Age

65 - 80 Years

Trial summary

Enrollment Goal
42
Trial Dates
May 2011 - December 2011
Phase
Phase 1
Could I Receive a placebo
Yes
Products
Vardenafil ODT (BAY38-9456)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
New Orleans Center for Clinical ResearchKnoxville, 37920, United States
Completed
Clinical Pharmacology of Miami, Inc.Miami, 33014, United States

Primary Outcome

  • The primary pharmacodynamic variable (endpoint) is the placebo-corrected mean maximal decrease in supine systolic blood pressure from baseline (1 hour before dose) to within 8 hours of dosing with 10 mg ODT formulation of vardenafil HCl and nifedipine.
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine.
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Mean maximal decrease in standing SBP
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Mean maximal decrease in standing diastolic blood pressure (DBP)
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Mean maximal decrease in supine DBP
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Mean maximal orthostatic change in SBP (the supine SBP minus the standing SBP)
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Mean maximal increase in supine and standing heart rate
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Mean area under effect curve (AUEC) in standing and supine systolic and diastolic blood pressure, and heart rate
    date_rangeTime Frame:
    Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
    enhanced_encryption
    Safety Issue:
    Yes
  • Safety parameters
    Safety parameters included physical examinations, adverse events, laboratory values, electrocardiogram, concomitant medications, and vital signs
    date_rangeTime Frame:
    up to end of study
    enhanced_encryption
    Safety Issue:
    Yes
  • Pharmacokinetics parameter
    date_rangeTime Frame:
    1 and 2 weeks prior to the Day 1 dosing of the combination of nifedipine/vardenafil as well as at Visit 4 and Visit 5
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Double-Blind Study to Evaluate the Pharmacodynamic Interaction between 10 mg vardenafil ODT (Orally Disintegrating Tablet) and Procardia XL® (nifedipine GITS) in Elderly Male Patients with both Hypertension and Erectile Dysfunction
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
Randomized
Blinding
Double Blind
Assignment
Crossover Assignment
Trial Arms
2